Skip to main content

Advertisement

Primary Kaposi’s sarcoma of the nasal cavity: a case report and review of the literature

Article metrics

  • 1520 Accesses

  • 7 Citations

Abstract

Background

Kaposi sarcoma is a neoplastic vascular disorder. It usually present on the skin of the upper and lower extremities, rarely in the mucosa of the head and neck. The most common sites reported are within the oral cavity, particularly on the palate. Other mucosal sites are rare. We present an unusual case where the primary manifestation of the Kaposi’s sarcoma was in the nasal mucosa.

Case presentation

A 56-year-old female of Mediterranean descent presented with a 1 year history of swelling on the left side of her nose, nasal obstruction and occasional minor epistaxes. Physical examination showed a firm and bulging polypoid mass which filled the left nasal cavity without cutaneous lesions.

Computed tomography (CT) demonstrated a tumor, measuring 77 mm in diameter, occupying the left nasal cavity causing erosion of nasal septum and extending posteriorly to the left choana and nasopharynx. There was bilateral cervical lymphadenopathy. Patient treated with chemotherapy alone. She was in a complete response after the first cycle. The patient received no further treatment. She needs a regular medical checkups that include a review of a patient’s medical history and a complete physical exam. She is in excellent local control over 12 months.

Conclusions

A review of the literature revealed that only seven cases of primary Kaposi sarcoma of the nasal cavity have previously been published and only two of them presented in a patient not associated with the acquired immunodeficiency syndrome. Here, we report the third case where the primary manifestation of the Kaposi sarcoma was in the nasal cavity in a patient with an adequate immune system.

Background

Kaposi’s sarcoma (KS) is a low-grade vascular tumor associated with infection with human herpesvirus 8 (HHV-8), also known as the KS-associated herpesvirus (KSHV) [1, 2].

The disease is named after Moritz Kaposi, a Hungarian dermatologist on the faculty of the University of Vienna, who first described the entity in 1872 as “idiopathic multiple pigmented sarcoma of the skin” [3]. The most recurrently affected sites are the skin and mucous membrane [4, 5], however, it can be found in other parts of the body: lungs, stomach, intestine [68], etc.

The KS of the head and neck usually involves the mucous membranes of the oral cavity, but it can be found in the pharynx, larynx, and tonsillar [918]. Isolated nasal location is extremely rare [1923].

A review of the literature revealed that there are a few reported cases of KS involving the head and neck region. In fact, only seven had primary presentation in the nasal cavity and two of them were not AIDS related [20, 21, 2426].

Here, we present a case of KS of the left nasal cavity in HIV negative patient, treated by chemotherapy only.

Case report

A 56-year-old female of Mediterranean descent presented with a 1 year history of swelling on the left side of her nose, nasal obstruction and occasional minor epistaxes. Physical examination showed a firm and bulging polypoid mass which filled the left nasal cavity without cutaneous lesions.

Computed tomography (CT) (Fig. 1) demonstrated a tumor, measuring 77 mm in diameter, occupying the left nasal cavity causing erosion of nasal septum and extending posteriorly to the left choana and nasopharynx. There was bilateral cervical lymphadenopathy.

Fig. 1
figure1

a Axial CT, b Coronal CT: demonstrated a tumor occupying the left nasal cavity causing erosion of nasal septum and extending posteriorly to the left choana and nasopharynx

A biopsy specimen was obtained in the nasal cavity. Initially, the diagnosis of angiosarcoma was made. After multidisciplinary consultation meeting, a second pathological opinion was required. Original slides examination revealed a submucosal proliferation composed of intersecting ill-defined fascicles, of spindled cells with mild to moderate nuclear atypia. Slit-like spaces containing red blood cells were noted. Intracytoplasmic and variably sized hyaline globules were seen in some tumor cells. Immunohistochemical study revealed a strong expression of CD31, CD34, and vimentin. Tumor cells showed negative staining for AE1/AE3, CK5/6, HMB-45, and melan-A. As tissue was depleted in the paraffin block, we were unable to perform further immunohistochemical testing, using HHV 8 antibody. A final diagnosis of Kaposi’s sarcoma was rendered.

A chest CT did not showed metastases in the lungs.

Decision in multidisciplinary consultation meeting is to instaure neoadjuvant chemotherapy because surgical excision is not feasible. Then an evaluation must be performed. Chemotherapy drugs ifosfamide (IFO) and doxorubicin (DOXO) was started on December 22, 2014. The detailed treatment regimen was as follows: IFO 1800 mg/m2 i.v. d1-5; mesna dose is 100 % of the IFO dose (3 g) i.v. d1-5 and DOXO 60 mg/m2 d1.

The cycle was repeated every 21 days. Physical examination after the first cycle of treatment showed a complete response. To keep the clinical response, the patient continued chemotherapy until four cycles. The fourth cycle date April 27, 2015.

Computed tomography (CT) of evaluation showed a near complete response in the nasal cavity (Fig. 2).

Fig. 2
figure2

Axial computed tomography (CT) of evaluation showed a near complete response in the nasal cavity

The patient received no further treatment. She needs a regular medical checkups that include a review of a patient’s medical history and a complete physical exam. She is in excellent local control over 12 months.

Discussion

Sinonasal cancers, which account for 3 % of all head and neck cancers, have their origin in the nasal cavity in 20–30 % of cases [27]. It is relatively uncommon [2830], with an incidence of 0.75 per 100,000 in the United States. This is a heterogeneous group of uncommon neoplasms including adenocarcinomas, malignant melanomas and non-Hodgkin’s lymphomas, followed in frequency by sarcomas, esthesioneuroblastomas, hemangiopericytomas, plasmacytomas, and anaplastic carcinomas [3134].

KS is an important opportunistic disease, which frequently occurs in HIV-positive patients. The incidence of KS involving head and neck was reported to be as high as 40–67 %, in which the cutaneous lesions predominate [25, 26].

However, the involvement of this region is only 14 % of patients with HIV-negative [24, 3541].

Here, we reported a case de Kaposi’s sarcoma of the nasal cavity in patient with HIV-negative.

KS involvement has been observed in almost all visceral sites, including lymph nodes, liver, pancreas, heart, the testes, bone marrow, bone, skeletal muscle and mucosa of head and neck [42, 43].

The most frequent sites of noncutaneous disease are the oral cavity, gastrointestinal tract, and respiratory system [4448].

There is a few cases of the Kaposi’s sarcoma in the nasal mucosa [25, 26, 49].

In a review of the literature, seven cases of the Kaposi’s sarcoma in the nasal mucosa were reported.

Gnnep et al. discussed nine cases of KS arising in the head and neck region. One of them was in the nose-mucocutaneous junction with HIV-negative, treated by surgical excision and relapsed at 9 months [24].

The second case of the KS in the nasal cavity with an adequate immune system was reported by Ioannis Venizelos et al. It was a case of a 59 year-old woman who presented a tumor arising from the left nasal septum which was excised. The patient received no further treatment and 4 years later, she is in excellent condition [21].

Three patients with HIV-positive who had KS of the nasal cavity, were treated by surgical excision. One of them relapsed at 2 months [20, 25, 26].

Patients with tumors of the nasal cavity usually present with a history of chronic sinus congestion and recurrent nasal obstruction. In our case, there was no ulceration of the overlying squamous epithelium and the patient presented with swelling on the left side of her nose, nasal obstruction and occasional minor epistaxes.

Various clinicopathologic forms of Kaposi’s sarcoma have been described, which often have overlapping features (patch, plaque, nodular, lymphadenopathic, infiltrative, florid, telangiectatic, ecchymotic, keloidal, angiomatous, inflammatory, pleomorphic, lymphangiomatous, and generalized lymphedema). In the earliest stage of Kaposi sarcoma, a flat lesion made of miniature vessels surrounding larger ectatic vessels is noted [50, 51].

In the more advanced stage of the disease, a discernible but relatively bland spindle cell component, centered around the proliferating vascular channels, can be described. Coalescent foci of spindle cells produce the classic nodular lesions of Kaposi sarcoma [51].

The spindle cells are separated by slit and sieve-like spaces containing erythrocytes and vascular channels. Lymphocytes and plasma cells, hemosiderin deposits, and dilated vessels are commonly seen at the periphery. Both intracellular and extracellular hyaline globules may be identified [52].

The tumor cells are strongly immunoreactive for CD31, CD34, factor VIII–related antigen, and Latent nuclear antigen-1 of HHV-8 (Kaposi sarcoma-associated herpes virus. They are variably immunoreactive for smooth muscle actin and are negative for cytokeratins (AE1/AE3 and CAM 5.2). The nuclear positivity using the LANA-1 antibody confirms the diagnosis [50, 51, 53].

The histologic differential diagnoses of Kaposi’s sarcoma include angiosarcoma, fibrosarcoma, arteriovenous malformations, and spindle cell hemangioendothelioma.

Clinicopathological features, mainly immunohistochemical studies, help by excluding these differential diagnoses, but some cases with unusual findings can pose a challenge to general pathologists [50, 52, 53].

The major goals of treatment are symptom palliation, prevention of disease progression, and shrinkage of tumor to alleviate edema, organ compromise, and psychological stress [54].

For HIV-positive patients who develop either limited or advanced Kaposi sarcoma (KS), it is recommended that treatment includes highly active antiretroviral therapy (ART).

Local treatment modalities are useful for cosmesis or the management of symptomatic bulky KS lesions, but they do not prevent the development of new lesions in untreated areas. The most widely used local treatment approaches include:

Intralesional chemotherapy with vinblastine, radiation therapy and topical alitretinoin.

Indications for systemic chemotherapy include extensive cutaneous disease, symptomatic visceral involvement, and cutaneous KS that is unresponsive to local therapy.

When chemotherapy is indicated, treatment with pegylated liposomal doxorubicin or liposomal daunorubicin is generally recommended as the first-line treatment for KS [55]. Other agents that have been used include paclitaxel, bleomycin, vinblastine, vincristine, and etoposide [56].

In our case, chemotherapy seems to be effective, since 8 months later the patient is in excellent condition without evidence of local recurrence or metastasis both clinically and radiologically.

Conclusions

Primary Kaposi sarcoma of the nasal cavity is a very rare entity. Our case represents the third reported case not associated with AIDS. Chemotherapy with doxorubicin seems to be effective with in excellent response.

Consent

Written informed consent was obtained from the patient for publication of this case report and any accompanying images.

References

  1. 1.

    Gao SJ, Kingsley L, Hoover DR, et al. Seroconversion to antibodies against Kaposi’s sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi’s sarcoma. N Engl J Med. 1996;335:233.

  2. 2.

    Martin JN, Ganem DE, Osmond DH, et al. Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med. 1998;338:948.

  3. 3.

    Kaposi M. Idiopathic multiple pigmented sarcoma of the skin. Arch Dematol Syphil. 1872;4:265–73.

  4. 4.

    Vaishnani JB, Bosamiya SS, Momin AM. Kaposi’s sarcoma: a presenting sign of HIV. Indian J Dermatol Venereol Leprol. 2010;76(2):215.

  5. 5.

    Tan WC, Chan LC. Kaposi’s sarcoma: case report and treatment options. Med J Malaysia. 2011;66(4):383–4.

  6. 6.

    Hoskote SS, Patel VP. Pulmonary kaposi sarcoma in AIDS. Mayo Clin Proc. 2012;87(10):e77.

  7. 7.

    Kibria R, Siraj U, Barde C. Kaposi’s sarcoma of the stomach and duodenum in human immunodeficiency virus infection: endoscopic image of interest. Dig Endosc. 2010;22(3):241–2.

  8. 8.

    Ling J, Coron R, Basak P, Jesmajian S. Recurrent lower gastrointestinal bleeding due to primary colonic Kaposi’s sarcoma in a patient with AIDS. Int J STD AIDS. 2013;24(11):908–11.

  9. 9.

    Khammissa RAG, Pantanowitz L, Feller L. Oral HIV-associated kaposi sarcoma: a clinical study from the GaRankuwa Area. South Africa. AIDS Res Treat. 2012;2012:873171.

  10. 10.

    Fusetti M, Eibenstein A, Paloscia R, Goffredo F, Narciso P. A case of Kaposi sarcoma of the pharynx as a primary manifestation of the acquired immunodeficiency syndrome. Acta Otorhinolaryngol Ital. 1996;16(2):129–31.

  11. 11.

    Celenk F, Yilmaz M, Asal K, Ekinci O, Tokgoz N. AIDS-related primary Kaposi sarcoma of the nasopharynx. Ear Nose Throat J. 2011;90(6):E1–4.

  12. 12.

    Schiff NF, Annino DJ, Woo P, Shapshay SM. Kaposi’s sarcoma of the larynx. Ann Otol Rhinol Laryngol. 1997;106(7 pt 1):563–7.

  13. 13.

    Raikundalia KB. Kaposi’s sarcoma of tonsil. J Laryngol Otol. 1973;87(3):295–7.

  14. 14.

    Chetty R, Batitang S. Kaposi’s sarcoma of the tonsil. ORL. 1998;60(1):48–50.

  15. 15.

    Sikora AG, Shnayder Y, Yee H, DeLacure MD. Oropharyngeal kaposi sarcoma in related persons negative for human immunodeficiency virus. Ann Otol Rhinol Laryngol. 2008;117(3):172–6.

  16. 16.

    Al-Brahim N, Zaki AH, El-Merhi K, Ahmad MS. Tonsillar kaposi sarcoma in a patient with membranous glomerulonephritis on immunosuppressive therapy. Ear Nose Throat J. 2013;92(7):E1–4.

  17. 17.

    Saxena S, Curry J, Tuluc M. Tonsillar Kaposi’s sarcoma: case report and review of the literature. Int J Oral Maxillofac Pathol. 2013;4(1):76–9.

  18. 18.

    Pittore B, et al. Isolated kaposi sarcoma of the tonsil: a case report and review of the scientific literature. Case Rep Otolaryngol. 2015;2015:874548. doi:10.1155/2015/874548.

  19. 19.

    Shevchenko AM, et al. Kaposi’s sarcoma with the primary lesion in the nasal cavity. Vestn Otorinolaringol. 1984;(3):73–4 (in Russian).

  20. 20.

    Wyatt ME, Finlayson CJ, Moore-Gillon V. Kaposi’s sarcoma masquerading as pyogenic granuloma of the nasal mucosa. J Laryngol Otol. 1998;112(3):280–2.

  21. 21.

    Venizelos Ioannis, Andreadis Charalambos. Zoi Tatsiou “Primary Kaposi’s sarcoma of the nasal cavity not associated with AIDS”. Eur Arch Otorhinolaryngol. 2008;265:717–20. doi:10.1007/s00405-007-0505-8.

  22. 22.

    Zenger VG, et al. Kaposi’s sarcoma in the nasal cavity. Vestn Otorinolaringol. 2008;(3):66–7 (in Russian).

  23. 23.

    Chen et al. Iatrogenic Kaposi’s sarcoma in nasal cavity: a casereport. World J Surg Oncol. 2014;12:172. http://www.wjso.com/content/12/1/172.

  24. 24.

    Gnepp DR, Chandler W, Hyams V. Primary Kaposi’s sarcoma of the head and neck. Ann Intern Med. 1984;100:107–14.

  25. 25.

    StaVord SD, Herdman RCD, Forster S, et al. Kaposi’s sarcoma of the head and neck in patients with AIDS. J Laryngol Otol. 1989;103:379–82.

  26. 26.

    Lucente FE. Kaposi’s sarcoma of the head and neck in patients with acquired immunodeficiency syndrome. Otolaryngol Head Neck Surg. 1994;111(5):618.

  27. 27.

    Robin PE, Powell DJ, Stansbie JM. Carcinoma of the nasal cavity and paranasal sinuses: incidence and presentation of different histological types. Clin Otolaryngol Allied Sci. 1979;4:431–56624.

  28. 28.

    Batsakis JG. Mucous gland tumors of the nose and paranasal sinuses. Ann Otol Rhinol Laryngol. 1970;79:557–62.

  29. 29.

    Roush G. Epidemiology of cancer of the nose and paranasal sinuses: current concepts. Head Neck Surg. 1979;2:3–11.

  30. 30.

    Halperin EC, Perez CA, Brady LW, editors. Perez and Brady's principles and practice of radiation oncology. Philadelphia, PA: Wolters Kluwer; 2013.

  31. 31.

    Spiro JD, Soo KC, Spiro RH. Nonsquamous cell malignant neoplasms of the nasal cavities and paranasal sinuses. Head Neck. 1995;17(2):114–8.

  32. 32.

    Manning JT, Batsakis JG. Pathology consultation: salivarytype neoplasms of the sinonasal tract. Ann Otol Rhinol Laryngol. 1991;100:691–4.

  33. 33.

    Calderon-Garciduenas L, Delgado R, Calderon-Garciduenas A, et al. Malignant neoplasms of the nasal cavity and paranasal sinuses: a series of 256 patients in Mexico City and Monterrey. Is air pollution the missing link? Otolaryngol Head Neck Surg. 2000;122(4):499–508.

  34. 34.

    Beatty CW, Pearson BW, Kern EB. Carcinoma of the nasalseptum: experience with 85 cases. Otolaryngol Head Neck Surg. 1982;90(1):90–4.

  35. 35.

    Harawi SJ, O’Hara CL. Pathology and pathophysiology of AIDS and HIV-related diseases. St Louis: C. V. Mosby; 1989. p. 83–134.

  36. 36.

    La Ferla L, Pinzone MR, Nunnari G, et al. Kaposi’s sarcoma in HIV-positive patients: the state of art in the HAART-era. Eur Rev Med Pharmacol Sci. 2013;17(17):2354–65.

  37. 37.

    Beral V, Peterman TA, Berkelman RL, Jaffe HW. Kaposi’s sarcoma among persons with AIDS: a sexually transmitted infection? Lancet. 1990;335:123.

  38. 38.

    Stefan DC, Stones DK, Wainwright L, Newton R. Kaposi sarcoma in South African children. Pediatr Blood Cancer. 2011;56:392.

  39. 39.

    Senba M, Buziba N, Mori N, et al. Increased prevalence of Kaposi’s sarcoma-associated herpesvirus in the Kapos’s sarcoma-endemic area of western Kenya in 1981–2000. Acta Virol. 2011;55:161.

  40. 40.

    Iscovich J, Boffetta P, Winkelmann R, et al. Classic Kaposi’s sarcoma in Jews living in Israel, 1961–1989: a population-based incidence study. AIDS. 1998;12:2067.

  41. 41.

    Fenig E, Brenner B, Rakowsky E, et al. Classic Kaposi sarcoma: experience at Rabin Medical Center in Israel. Am J Clin Oncol. 1998;21:498.

  42. 42.

    Ioachim HL, Adsay V, Giancotti FR, et al. Kaposi’s sarcoma of internal organs. A multiparameter study of 86 cases. Cancer. 1995;75:1376.

  43. 43.

    Caponetti G, Dezube BJ, Restrepo CS, Pantanowitz L. Kaposi sarcoma of the musculoskeletal system: a review of 66 patients. Cancer. 2007;109:1040.

  44. 44.

    Nichols CM, Flaitz CM, Hicks MJ. Treating kaposi’s lesions in the HIV-infected patient. J Am Dent Assoc. 1993;124:78.

  45. 45.

    Danzig JB, Brandt LJ, Reinus JF, Klein RS. Gastrointestinal malignancy in patients with AIDS. Am J Gastroenterol. 1991;86:715.

  46. 46.

    Laine L, Amerian J, Rarick M, et al. The response of symptomatic gastrointestinal kaposi’s sarcoma to chemotherapy: a prospective evaluation using an endoscopic method of disease quantification. Am J Gastroenterol. 1990;85:959.

  47. 47.

    Haramati LB, Wong J. Intrathoracic kaposi’s sarcoma in women with AIDS. Chest. 2000;117:410.

  48. 48.

    Huang L, Schnapp LM, Gruden JF, et al. Presentation of AIDS-related pulmonary kaposi’s sarcoma diagnosed by bronchoscopy. Am J Respir Crit Care Med. 1996;153:1385.

  49. 49.

    Barnes L, Eveson J, Reichart P. In World Health Organization classification of tumours, pathology and genetics of head and neck tumours. Lyon: IARC Press; 2005. p. 193–4.

  50. 50.

    Rakheja D, et al. Pathologic quiz case: upper aerodigestive tract mass in a 90-year-old woman. Arch Pathol Lab Med. 2003;127(6):e279–80.

  51. 51.

    Weiss SW, Goldblum JR, editors. Enzinger and Weiss’s Soft Tissue Tumors. 5th ed. St Louis: Mosby Inc; 2008.

  52. 52.

    Makharoblidze E, Goishvili N, Mchedlishvili M, Jangavadze M. Primary kaposi’s sarcoma of the heart in non-immunodeficient patient: case report and literature review. Diagn Pathol. 2015;10:111. doi:10.1186/s13000-015-0354-5.

  53. 53.

    Chen Kuang-Hua, Chen Tai-Di, Chen Chiang-Wen, Lee Li-yu. Iatrogenic kaposi’s sarcoma in nasal cavity: a case report. World J Surg Oncol. 2014;12:172. doi:10.1186/1477-7819-12-172.

  54. 54.

    Dezube BJ, Pantanowitz L, Aboulafia DM. Management of AIDS-related kaposi sarcoma: advances in target discovery and treatment. AIDS Read. 2004;14:236.

  55. 55.

    Bower M, Collins S, Cottrill C, et al. British HIV Association guidelines for HIV-associated malignancies 2008. HIV Med. 2008;9:336.

  56. 56.

    Lee FC, Mitsuyasu RT. Chemotherapy of AIDS–related kaposi’s sarcoma. Hematol Oncol Clin North Am. 1996;10:1051.

Download references

Authors’ contributions

KM, MK, AS, and SL were the major contributors in writing the manuscript. HE, TK, SM and NB cared for the patient during her time in the hospital and assisted in the data collection and the preparation of the manuscript. All authors read and approved the final manuscript.

Acknowledgements

All authors are thankful for providing the necessary facilities for the preparation of the manuscript. Special thanks are due to the Faculty of Medicine and Pharmacy of Rabat, the source(s) of funding for all authors.

Competing interests

The authors declare that they have no competing interests.

Author information

Correspondence to Karima Mouden.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mouden, K., Khmou, M., Loughmari, S. et al. Primary Kaposi’s sarcoma of the nasal cavity: a case report and review of the literature. Clin Sarcoma Res 6, 4 (2016) doi:10.1186/s13569-016-0044-4

Download citation

Keywords

  • Kaposi sarcoma
  • Nasal cavity
  • Adequate immune system
  • Chemotherapy